Top-News

Idorsia Aktie News

Aktie
WKN:  A2DTEB ISIN:  CH0363463438 US-Symbol:  IDRSF Branche:  Biotechnologie Land:  Schweiz
4,075 €
-0,005 €
-0,12%
07:30:21 Uhr
Depot/Watchlist
Marktkapitalisierung *
618,49 Mio. €
Streubesitz
55,25%
KGV
-0,58
Dividende
11,03 €
Dividendenrendite
268,74%
Index-Zuordnung
-

Idorsia News

30.07.25 - GlobeNewswire
Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results
Ad hoc announcement pursuant to Art. 53 LR
23.07.25 - GlobeNewswire
Invitation to Idorsia's HY 2025 Financial Reporting webcast and conference call with our new CEO Srishti Gupta
Idorsia will publish its Half Year 2025 Financial Reporting on Wednesday July 30, at 07:00 CEST.
30.06.25 - GlobeNewswire
A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans
Ad hoc announcement pursuant to Art. 53 LR
25.06.25 - GlobeNewswire
Bondholders approve amended terms of the 2025 and 2028 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR
25.06.25 - GlobeNewswire
Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR
23.06.25 - GlobeNewswire
Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement
Ad hoc announcement pursuant to Art. 53 LR
10.06.25 - GlobeNewswire
Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia
Ad hoc announcement pursuant to Art. 53 LR
06.06.25 - GlobeNewswire
Idorsia publishes invitations to bondholder meetings
Ad hoc announcement pursuant to Art. 53 LR
28.05.25 - GlobeNewswire
Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2025
Allschwil, Switzerland – May 28, 2025 At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all ...
21.05.25 - GlobeNewswire
New funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia’s path to profitability
Ad hoc announcement pursuant to Art. 53 LR
02.05.25 - GlobeNewswire
Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders
Allschwil, Switzerland – May 2, 2025 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of ...
30.04.25 - GlobeNewswire
Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset
Ad hoc announcement pursuant to Art. 53 LR
29.04.25 - GlobeNewswire
New data with daridorexant assessing the transition from night to day in insomnia disorder published in Sleep Medicine
Daridorexant improved sleep maintenance throughout the entire night, including the last quarter, while also improving next-​morning sleepiness. Daridorexant improved next-...
16.04.25 - GlobeNewswire
Higher cantonal composition authority approved the amendments to the terms of the 2025 convertible bond
Ad hoc announcement pursuant to Art. 53 LR
09.04.25 - GlobeNewswire
The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension
Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria in Black patients with confirmed ...
09.04.25 - GlobeNewswire
US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement
Allschwil, Switzerland – April 9, 2025 Idorsia Ltd (SIX: IDIA) today announced that the US Food & Drug Administration (FDA), after having released TRYVIO from its REMS (Risk ...
27.03.25 - GlobeNewswire
Idorsia publishes its Annual Report 2024
Ad hoc announcement pursuant to Art. 53 LR
17.03.25 - GlobeNewswire
US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients
Ad hoc announcement pursuant to Art. 53 LR
14.03.25 - GlobeNewswire
Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia
Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-​related endpoints in a placebo-​controlled study in patients with ...
04.03.25 - GlobeNewswire
Idorsia announces financial results for 2024
Ad hoc announcement pursuant to Art. 53 LR

Newssuche

Videos

newspaper
08.12.25 +5,61%
Technical Trading: Die besten 3 Tage
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »